BNTC NASDAQ
Benitec Biopharma Inc.
1W: -3.3%
1M: -10.9%
3M: -6.4%
YTD: -1.8%
1Y: -25.0%
3Y: +196.2%
5Y: -85.5%
$11.89
+0.31 (+2.68%)
Weekly Expected Move ±6.8%
$10
$11
$11
$12
$13
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$408.5M
52W Range9.85-16.76
Volume77,896
Avg Volume111,114
Beta0.25
Dividend$0.77
Analyst Ratings
Company Info
CEOJerel A. Banks
Employees19
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-24
Websitebenitec.com
3940 Trust Way
Hayward, CA 94545
US
Hayward, CA 94545
US
510 780 0819
About Benitec Biopharma Inc.
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.
Latest News
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BUCHI J KEVIN | G-Gift | 51,813 | — | 2026-06-29 |
| Friedman David Matth | A-Award | 35,000 | $11.45 | 2026-05-26 |
| Friedman David Matth | 0 | — | 2026-05-22 | |
| Mates Sharon | A-Award | 31,500 | $12.83 | 2026-01-22 |
| SUVRETTA CAPITAL MAN | P-Purchase | 65,800 | $13.44 | 2025-12-29 |